Skip to content
lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alvotech
Alvotech announces successful closure of FDA inspection of manufacturing facility
July 29, 2026
Alvotech further strengthens liquidity by securing term loan facility of $75 million
July 1, 2026
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
June 18, 2026
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 18, 2026
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
June 16, 2026
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 15, 2026
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
June 8, 2026
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 4, 2026
Main Results of 2026 Annual and Extraordinary General Meeting
June 3, 2026
Alvotech to present at upcoming investor conferences in June
June 2, 2026
1
2
Next Page
→